Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967304 · ClinicalTrials.gov registry record · Phase 4
Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism
A Phase 4 study, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,779
- Enrollment target
NCT00967304 is a Phase 4 study that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 2,779 participants.
The verdict
NCT00967304, a Phase 4 study, has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,779 participants
- Enrollment target
Study Summary
The main objective of this study is to verify whether a new clinical decision rule identifying patients diagnosed with unprovoked blood clots who have a low risk of recurrence can safely stop oral anticoagulant therapy after 5-7 months of treatment.
Interventions
- OTHER Application of the"Men continue and HER DOO2" rule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,779 participants |
| Start Date | 2008-11 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967304
The ClinicalTrials.gov registry entry for NCT00967304 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,779 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Hospital Research Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Application of the"Men continue and HER DOO2" rule is the first listed.
NCT00967304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00967304 about?
NCT00967304 is a clinical study titled "Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism". The main objective of this study is to verify whether a new clinical decision rule identifying patients diagnosed with unprovoked blood clots who have a low risk of recurrence can safely stop oral anticoagulant therapy after 5-7 months of treatment.
What is the current status of trial NCT00967304?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,779 participants. The study started on 2008-11. Estimated completion is 2016-07.
What interventions are being tested in trial NCT00967304?
The interventions under investigation include: Application of the"Men continue and HER DOO2" rule (OTHER).
Who is sponsoring clinical trial NCT00967304?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.